View Author
scopus: 24169123100
Jongen-Lavrencic, M.
(Mojca Jongen-Lavrencic)Supervisor (promotor) of 1 dissertation
patient expression mirna microrna treatment leukemia group myeloid leukemia hsa-mir survival study blood myeloid cytogenetic induction remission cycle signi level university table cancer sample hospital square meter sqstm analysis cluster chemotherapy status abnormality daunorubicin number figure erasmus university deletion result sqstm 1 erasmu value control escalated-dose group chromosome donor-derived bm mscs factor square mutation mir -15a meter center event-free survival conventional-dose group signi ficantly death erasmus mc target performance status course event-free protein cytarabine difference allogeneic hsct effect cytogenetic findings nejm.org trial ficantly therapy escalated-dose differentiation 60 years csf 3r expression levels mir -150 hematopoietic correlation performance society allogeneic
10 Most Recent Publications
|
The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands
(Article)
Leunis, A. Blommestein, H.M. Huijgens, P.C. Blijlevens, N.M. Jongen-Lavrencic, M. Uyl-de Groot, C.A. |
2012-10-15
|
|
Transition of highly specific microRNA expression patterns in association with discrete maturation stages of human granulopoiesis
(Article)
Sun, S.M. Dijkstra, M.K. Bijkerk, A. Brooimans, R.A. Valk, P.J.M. Erkeland, S.J. Löwenberg, B. Jongen-Lavrencic, M. |
2011-11-01
|
|
MicroRNA signatures characterize multiple myeloma patients
(Article)
Corthals, S.L. Sun, S.M. Zweegman, S. Jongen-Lavrencic, M. Sonneveld, P. Kuiper, R. Knegt, Y. de Broyl, A. Holt, B. van der Beverloo, H.B. Peeters, J.K. Jarari, L. Lokhorst, H.M. |
2011-11-01
|
|
MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice
(Article)
Meenhuis, J.C.M. Veelen, P. van Demmers, J.A. Jongen-Lavrencic, M. Löwenberg, B. Touw, I.P. Sharp, P.A. Erkeland, S.J. Looper, H. de Boxtel, N. van Berg, T.I.J. van den Sun, S.M. Taskesen, E. Stern, P. Ru, A. de Adrichem, A.J. van |
2011-07-28
|
|
Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
(Article)
Corthals, S.L. Jongen-Lavrencic, M. Knegt, Y. de Peeters, J. Beverloo, H.B. Lokhorst, H.M. Sonneveld, P. |
2010-05-01
|
|
Gemtuzumab ozogamicin as postremission treatment inAMLat 60 years of age or more: results of a multicenter phase 3 study
(Article)
Löwenberg, B. Beck, J.A. Biemond, B.J. Vellenga, E. Breems, D.A. Muijnck, H. de Schaafsma, R. Verhoef, G. Döhner, H. Gratwohl, A. Pabst, T. Ossenkoppele, G.J. Graux, C. Maertens, J. Putten, W.L.J. van Schouten, H.C. Verdonck, L.F. Ferrant, A. Sonneveld, P. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2010-04-01
|
|
High-dose daunorubicin in older patients with acute myeloid leukemia
(Article)
Löwenberg, B. Ossenkoppele, G.J. Biemond, B.J. Vellenga, E. Marwijk Kooy, M. van Verdonck, L.F. Beck, J.A. Döhner, H. Gratwohl, A. Pabst, T. Verhoef, G.E.G. Putten, W.L.J. van Schouten, H.C. Graux, C. Ferrant, A. Sonneveld, P. Maertens, J. Jongen-Lavrencic, M. Lilienfeld-Toal, M. Von |
2009-09-24
|
|
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
(Letter To Editor)
Dijkstra, M.K. Lom, K. van Tielemans, D. Elstrodt, F. Langerak, A.W. Veer, M.B. van 't Jongen-Lavrencic, M. |
2009-01-01
|
|
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
(Article)
Jongen-Lavrencic, M. Sun, S.M. Dijkstra, M.K. Valk, P.J.M. Löwenberg, B. |
2008-05-15
|
|
miRNA analysis in B-cell chronic lymphocytic leukaemia: Proliferation centres characterized by low miR-150 and high BIC/miR-155 expression
(Article)
Wang, M. Tan, L.P. Visser, L. Jongen-Lavrencic, M. Kluin, P.M. Berg, A. van den Dijkstra, M.K. Lom, K. van Robertus, J.L. Harms, G. Blokzijl, T. Kooistra, K. t'Veer, M.B. van Rosati, S. |
2008-05-01
|
